To enhance the therapeutic effects in vivo, the combinational use of different mAbs, such as H2Mab-19 and EpMab-16 may be required to treat HER2 and/or EpCAM-expressing CRC cells. The gene discussed is EPCAM; the disease is colorectal carcinoma.